Sandra Silvestri: Did you know that NET account for 20% of lung cancers
“Did you know that neuroendocrine tumors (NETs) account for 20% of lung cancers?
It’s only been two months since I last shared about the challenges people living with neuroendocrine cancer face. However, it was World NET Cancer Day on Sunday, so I wanted to again highlight this relatively uncommon cancer that has a growing incidence rate.
While the healthcare industry is working to advance treatment options for those diagnosed with advanced-stage NETs, patient advocacy groups like International Neuroendocrine Cancer Alliance are raising awareness and developing resources to help HCPs detect NETs as early as possible.
We know it will take a combination of earlier diagnosis and innovative new therapies to turn the tide on cancer, and there is still much work to be done.”
Proceed to the video attached to the post.
For more posts like this, visit oncodaily.com.
Sandra Silvestri, MD, PhD, is the Before joining Ipsen, she held several senior leadership roles at Sanofi, including her most recent position as Senior Vice President and Global Medical Head for the General Medicine Global Business Unit, as well as Senior Medical Director role at Eli Lilly.
Sandra is a Member of the Board of Directors at GENFIT. She is also engaged as a professor at the medical schools of the University of Florence in Italy and Descartes University in Paris.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023